1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Cell Therapy
  6.  » Accelerating Manufacturing for Next Generation hiPSC-Based Clinical Therapies

Accelerating Manufacturing for Next Generation hiPSC-Based Clinical Therapies

Summary: Human induced pluripotent stem cell (hiPSC)-based therapy is currently at the forefront of technology boom and is advancing at a rapid pace. Generating hiPSCs under current Good Manufacturing Practice (cGMP) conditions, tissue sourcing, testing, and scale of production, are now considered as critical components of both clinical and commercial successes. In this webinar, the presenters will share their experiences with development and manufacturing of hiPSCs. The expert panel will highlight key considerations for driving clinical and commercial success with hiPSCs as starting materials, including aspects such as their derivation, expansion, and differentiation. The experts will also share strategies that can improve the speed, quality, cost of goods, differentiation, and scaling up of hiPSC-based therapies.

Click here to view the webinar